Novo Nordisk A/S vs United Microelectronics Corp — how do they compare? Novo Nordisk A/S trades at $38.6 (market cap $165.31B), while United Microelectronics Corp trades at $22.89 (market cap $58.02B). The key difference: Novo Nordisk A/S is far larger — about 2.8× United Microelectronics Corp's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and United Microelectronics Corp for 42 Days on average.
| NVO | UMC | |
|---|---|---|
Market Cap | $165.31B | $58.02B |
Volume | 11,432,838 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $63.98 | $28.02 |
52-Week Low | $35.29 | $7.02 |
Typical Hold Time | 116 Days | 42 Days |
Enterprise Value | $179.56B | $55.10B |
Dividend Yield | 4.71% | 1.76% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
United Microelectronics (UMC) trades at $22.96, down 1.5% on the day, with strong fundamental performance including three consecutive quarterly earnings beats. The stock shows a bullish technical signal despite bearish moving averages, with support at $22 and resistance at $23-24. Revenue growth is projected to accelerate from $237.6B in 2025 to $250.7B in 2026, while net income margins are expected to improve significantly from 16.99% to 32.75%.
UMC presents a compelling investment case with robust earnings momentum and improving profitability, though mixed analyst sentiment and competitive pressures in the semiconductor foundry space warrant caution. The stock's current valuation (P/E 22.03, P/S 7.15) appears reasonable given projected earnings growth, but investors should monitor AI spending trends and capacity utilization rates that drive semiconductor demand cycles.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →